Please assess the completion status of the following clinical trial:

Trial Title: Nexium Study To Suppress Nausea During Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For inclusion, participants must:~* be female, age 18 years or older~* sign an informed consent~* have Stage I, II, or III breast cancer~* be receiving at least four cycles of anthracycline-based chemotherapy which may include: doxorubicin/cyclophosphamide AC),5-fluorouracil/doxorubicin/cyclophosphamide (FAC), fluoruracil/epirubicin/cyclophosphamide (FEC) or dose dense chemotherapy regimen (AC every two weeks) as their agents for neoadjuvant or adjuvant chemotherapy~* patient must receive a serotonin receptor antagonist and a steroid for premedication~* have a negative serum pregnancy test within 7 days prior to starting study if pre-menopausal~* have adequate renal function, defined by a serum creatinine within 1.5 times the upper limit of normal~* have adequate liver function, defined by a total bilirubin, SGOT, alkaline phosphatase and albumin within 1.5 times the upper limits of normal~* have adequate bone marrow function, defined as a WBC \>4.0, platelet count \>100K, and HCT \>30~* have no prior or current malignancies for which chemotherapy was utilized~* have a performance status of at least 2 according to the Eastern Cooperative Oncology Group World Health Organization or a Karnofsky score of 50% or greater.~Exclusion Criteria:~* pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential~* severe or underlying chronic illness or disease~* renal insufficiency or liver abnormalities~* chronic use of steroids~* uncontrolled GERD~* current use of proton pump inhibitors~* history of Barrett's esophagus~* history of erosive gastritis~* intolerance to serotonin receptor antagonists~* current use of aprepitant or palonosetron as antiemetics~* concomitant use of H2-receptor antagonists (ranitidine, cimetidine, famotidine or nizatidine) or metaclopramide

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole (Type: EXPERIMENTAL): Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
- Sugar pill (Type: PLACEBO_COMPARATOR): Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.

Based on this trial design, predict the completion outcome and termination type (if applicable).